LON:IMM ImmuPharma (IMM) Share Price, News & Analysis GBX 2.67 -0.07 (-2.66%) As of 03:08 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ImmuPharma Stock (LON:IMM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImmuPharma alerts:Sign Up Key Stats Today's Range 2.67▼ 2.6750-Day Range 2.15▼ 3.7252-Week Range 0.85▼ 7.40Volume20,230 shsAverage Volume8.42 million shsMarket Capitalization£11.34 millionP/E RatioN/ADividend Yield0.77%Price TargetN/AConsensus RatingN/A Company OverviewImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.Read More… Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IMM Stock News HeadlinesImmuPharma celebrates "significant milestone" for P140 platformMarch 14, 2025 | lse.co.ukImmuPharma addresses recent share price volatilityJanuary 28, 2025 | msn.comTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.May 28, 2025 | Paradigm Press (Ad)We Think ImmuPharma (LON:IMM) Needs To Drive Business Growth CarefullyJanuary 25, 2025 | finance.yahoo.comImmuPharma PLC (25I.MU)January 19, 2025 | ca.finance.yahoo.comSMALL CAP MOVERS: ImmuPharma lifted by groundbreaking researchJanuary 10, 2025 | msn.comAIM WINNERS & LOSERS: ImmuPharma jumps; Impax Asset hit by outflowsJanuary 9, 2025 | lse.co.ukImmuPharma Targets Global Partnerships at Key Biotech EventsJanuary 9, 2025 | markets.businessinsider.comSee More Headlines IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed this year? ImmuPharma's stock was trading at GBX 1.18 on January 1st, 2025. Since then, IMM shares have increased by 126.4% and is now trading at GBX 2.67. View the best growth stocks for 2025 here. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) released its quarterly earnings data on Monday, May, 19th. The company reported ($0.60) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative trailing twelve-month return on equity of 131.41%. How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), MOTIF BIO PLC/S (MTFB), Nikola (NKLA), Thor Energy (THR), Aminex (AEX) and GSK (GSK). Company Calendar Last Earnings5/19/2025Today5/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.51 million Net Margins3,519.56% Pretax MarginN/A Return on Equity-131.41% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio1.60 Quick Ratio1.03 Sales & Book Value Annual Sales£-71,310.29 Price / Sales-158.99 Cash FlowGBX 0.13 per share Price / Cash Flow20.50 Book ValueGBX 0.65 per share Price / Book4.13Miscellaneous Outstanding Shares425,094,500Free FloatN/AMarket Cap£11.34 million OptionableNot Optionable Beta1.53 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (LON:IMM) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.